Amylyx Pharmaceuticals (AMLX) Long-Term Debt Issuances (2021 - 2025)
Amylyx Pharmaceuticals (AMLX) recorded quarterly Long-Term Debt Issuances of -$375000.0 in Q4 2025, down 100.2% quarter-over-quarter from $191.1 million in Q3 2025.
Amylyx Pharmaceuticals (AMLX) Long-Term Debt Issuances (2021 - 2025) Analysis & Trends
Amylyx Pharmaceuticals' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at -$375000.0 for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$375000.0; the TTM figure through Dec 2025 stood at $256.3 million (changed N/A YoY), while the FY2025 annual figure was $256.3 million, changed N/A from the prior year.
- Long-Term Debt Issuances was -$375000.0 for Q4 2025 at Amylyx Pharmaceuticals, down from $191.1 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $191.1 million in Q3 2025 to a low of -$375000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.51 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Amylyx Pharmaceuticals | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -375,000.00 |
| Dec 31, 2025 | -375,000.00 |
| Sep 30, 2025 | 191.11 Mn |
| Sep 30, 2025 | 191.11 Mn |
| Mar 31, 2025 | 65.58 Mn |
| Mar 31, 2025 | 65.58 Mn |
| Mar 31, 2021 | 11.89 Mn |
| Mar 31, 2021 | 11.89 Mn |